AUTHORS
Amanda Blackmon, DO, Michelle Afkhami2, Timothy Martins, PhD3, Jieya Wu, MD4, Karamjeet Singh Sandhu, MD5, Brian John Ball, MD, MS6, Anthony Selwyn Stein, MD7, Vaibhav Agrawal, MD8, Ibrahim Aldoss, MD9, Andrew Artz, MD,MS10, Salman Otoukesh, MD11, Sunmin Park, MD PhD12, Jianying Zhang, PhD13, Diana Knobler14, Yueming Tang, MD,PhD15, Sarah Ursu16, Angelica Hamilton17, Marjorie Robbins, PhD18, Khyati Joshi19, Winston Lee, MD,PhD20, Guido Marcucci, MD21, Pamela S. Becker, MD, PhD22
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 University of Washington, Seattle, Washington, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, United States
15 City of Hope, Monrovia, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Monrovia, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
ABSTRACT
Introduction: Choosing effective therapy for patients with aggressive relapsed/refractory acute myeloid leukemia (AML) can be challenging given the marked heterogeneity of cytogenetic and molecular profiles. We therefore enrolled patients on a “Feasibility Study for Individualized Treatment for Acute Myeloid Leukemia Based on High Throughput Screening and Genomics Data” (NCT07613385). Leukemia cells were analyzed by both HopeSeq Heme Comprehensive testing (NGS for >500 genes and RNASeq for >5000 gene rearrangements as well as gene amplification or loss) and a custom high throughput drug screen (HTS) performed at a CLIA approved test site at the University of Washington that includes six triple drug regimens as well as targeted inhibitors (130 in all). Both sets of data were provided to the patient’s physician (5-6d for HTS, 12-14d for HopeSeq), and a functional and molecular tumor board (FMTB) was convened to discuss treatment options based on ranking of IC50s and drug sensitivity scores (DSS) known to correlate with clinical response (Breeze 2.0) and rationale for use of targeted agents from the molecular tests and/or drug screening. In addition, a rapid world literature search was conducted after inputting deidentified clinical features, as well as molecular and functional data using a Google platform called Capricorn developed in collaboration with Dr. Uri Ilan at the Princess Máxima Center, to inform the FMTB regarding similar cases or unique scientific discoveries related to the patient’s co-occurring mutations, cytogenetics, and/or gene rearrangements. The patient’s physician selected the regimen after clinical consideration and insurance authorization, and retrospective analysis will be conducted to determine the relative contribution to positive and negative predictive value of the molecular assay vs. the functional screen, with outcomes data at 6 and 12 months. We believe that this combination of multi-omic data including NGS, RNASeq, and functional testing as well as the focused literature search represents the state-of-the-art in providing a comprehensive precision medicine approach.
Study Procedures: Leukemia cells were obtained from blood and/or bone marrow, or for extramedullary involvement, tissue biopsies and/or fluid samples were obtained. Magnetic bead enrichment for CD34+ or CD117+ cells, as determined by flow cytometry phenotype. The primary objective was to assess feasibility of performing HopeSeq and HTS and obtaining individualized treatment recommendations from the FMTB within 18 days of sample acquisition. Feasibility was defined as success in at least 70% of evaluable participants.
Results: We completed our planned enrollment of 18 evaluable patients with results provided to physicians in the required timeframe. Thus, we have demonstrated that obtaining individualized treatment recommendations for AML based on HTS and genomics data is feasible. The age range was 23 to 80, median 46. There were 6 females and 12 males. There were 10 white non-Hispanic, 4 white Hispanic, 3 Asian non-Hispanic and 1 Black/African American non-Hispanic patients. The majority of patients had adverse ELN risk. The patients had up to six prior treatment regimens, including immunotherapy and up to 2 prior transplants. Correlative analysis between mutations and ex vivo drug sensitivity revealed that signaling pathway mutations were associated with the largest number of drug responses, while splicing factor mutations were associated with sensitivity to azacitidine. One patient achieved complete remission (CR) after previously failing a multi-agent intensive regimen and achieved both flow and molecular MRD negative CR after allogeneic transplant. Another pt achieved CR/NED by PET, 3 pts had MLFS, and others have not yet completed evaluation. The outcomes and survival (LFS/OS) will eventually be determined for all patients. The Capricorn literature search revealed scientific data that provided insight into treatment options, and became increasingly more helpful.
Summary and Future Work: This approach of combining comprehensive molecular and functional testing and correlation with published cases and scientific literature supporting treatment decisions may represent the best option for patients who have relapsed after aggressive treatment, transplants, and immunotherapy. This feasibility study paves the way for a definitive trial to prove superiority of this approach to conventional treatment or phase I trials.
DISCLOSURES
Amanda Blackmon, DO: No relevant conflicts of interest to declare.